Get to know our clinical trials
Clinical trial of RMC-6291 in combination with RMC-6236 in participants with advanced solid tumors with the KRASG12 mutation.
THE PURPOSE OF THIS STUDY IS TO ANALYZE A COMBINATION OF 2 NEW DRUGS CALLED RMC-6291 AND RMC-6236 (THE STUDY DRUGS). THIS STUDY WILL LOOK AT THE SAFETY AND ANTITUMOR EFFECTS OF RMC-6291 AND RMC-6236 WHEN GIVEN TOGETHER AT DIFFERENT DOSES IN PARTICIPANTS WITH KRASG12C-MUTATED SOLID TUMORS. IT WILL ALSO ANALYZE HOW THEIR BODY PROCESSES RMC-6291 AND RMC-6236 WHEN THEY ARE ADMINISTERED TOGETHER.
Technical Summary
- PHASE 1B, MULTICENTER, OPEN-LABEL, OPEN-LABEL, STEPWISE DOSE ESCALATION AND DOSE-ESCALATION STUDY OF RMC-6291 IN COMBINATION WITH RMC-6236 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS WITH THE KRASG12 MUTATION
- Code EudraCT: 2023-508178-27
- Protocol number: RMC-6291-101
- Promoter: Revolution Medicines, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.